193 related articles for article (PubMed ID: 10912779)
1. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
Zhou A; Yu L; Li J; Zhang J; Wang H
Hypertens Res; 2000 Jul; 23(4):391-7. PubMed ID: 10912779
[TBL] [Abstract][Full Text] [Related]
2. Renal protective effects of blocking the intrarenal renin-angiotensin system.
Li J; Zhou C; Yu L; Wang H
Hypertens Res; 1999 Sep; 22(3):223-8. PubMed ID: 10515446
[TBL] [Abstract][Full Text] [Related]
3. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
Haddad G; Amiri F; Garcia R
Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
[TBL] [Abstract][Full Text] [Related]
4. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
Li S; Cao B; Feng QH; Li XZ
Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
[TBL] [Abstract][Full Text] [Related]
5. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
Jover B; Herizi A; Casellas D; Mimran A
J Hypertens; 2001 Nov; 19(11):2039-46. PubMed ID: 11677370
[TBL] [Abstract][Full Text] [Related]
6. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
Taal MW; Brenner BM
Kidney Int; 2000 May; 57(5):1803-17. PubMed ID: 10792600
[TBL] [Abstract][Full Text] [Related]
8. Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors.
Niimi R; Nakamura A; Yanagawa Y
Jpn J Pharmacol; 2002 Feb; 88(2):139-45. PubMed ID: 11928713
[TBL] [Abstract][Full Text] [Related]
9. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Wada T; Kanagawa R; Ishimura Y; Inada Y; Nishikawa K
J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
12. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
Sugimoto K; Tsuruoka S; Matsushita K; Fujimura A
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
Cao Z; Cooper ME; Wu LL; Cox AJ; Jandeleit-Dahm K; Kelly DJ; Gilbert RE
Hypertension; 2000 Oct; 36(4):561-8. PubMed ID: 11040236
[TBL] [Abstract][Full Text] [Related]
14. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
15. ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models.
Taal MW; Brenner BM
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S51-6; discussion S61. PubMed ID: 10076921
[TBL] [Abstract][Full Text] [Related]
16. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Noda M; Matsuo T; Nagano-Tsuge H; Ohta M; Sekiguchi M; Shibouta Y; Naka T; Imura Y
Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
18. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y
Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of enalapril and irbesartan in experimental papillary necrosis.
Garber SL; Mirochnik Y; Arruda JA; Dunea G; Slobodskoy L
Kidney Blood Press Res; 2001; 24(1):39-43. PubMed ID: 11174005
[TBL] [Abstract][Full Text] [Related]
20. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
